Isotope production facility that Oklo will advance through the U.S. Department of Energy's Nuclear Energy Launch Pad, run by the National Reactor Innovation Center (NRIC). It pairs reactor irradiation with hot-cell processing (isotope separation, product recovery, packaging and transportation), builds on Oklo's Groves Isotope Test Reactor in Texas, and initially focuses on lutetium-177 and other therapeutic isotopes for radiopharmaceutical cancer treatments. Oklo plans to move from pilot operations to commercial-scale production, subject to U.S. Nuclear Regulatory Commission licences. Site, timeline and capacity were not stated in the announcement (October 13, 2026).